Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Alvo Pharma AB
AB
In liquidation
Org 5592178346
Research and experimental development on biotechnology · NACE 7211
Est. 2019
0 employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2021
SEK 0
EBITDA margin
—
+96% vs 2020
Equity ratio
95.5%
Financial strength
Net profit 2021
SEK -10K
+96% vs 2020
EBITDA — year on year
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
0%
2021
Key figures
Annual report 2021
Revenue
SEK 0
—
EBITDA
SEK -10K
+96%
Net profit
SEK -10K
+96%
Total assets
SEK 44K
-28%
Equity
SEK 42K
-18%
Employees
0
—
Company information
Legal name
Alvo Pharma AB
Org number
5592178346
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
9 september 2019
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska bedriva bioteknisk forskning och utveckla nya läkemedel och diagnostikmetoder.
Contact
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on biotechnology
Companies in
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
Income statement
SEK thousands
Item
2020
2021
Revenue
0
0
Staff expenses
—
—
EBITDA
−266
−10
Depreciation & amort.
−0
−0
EBIT
−266
−10
Net financials
—
—
Profit before tax
−266
−10
Tax
−0
−0
Net profit
−266
−10
Balance sheet
SEK thousands
Item
2020
2021
Total assets
61
44
Equity
51
42
Long-term debt
0
0
Short-term debt
10
3
Total debt
10
3
Financial ratios
5-year trend
EBITDA margin
-1000000.0%
This company
15.8%
Market median
-6329214% vs market
2020
2021
Equity ratio
95.5%
This company
38.2%
Market median
+150% vs market
2020
2021
Return on equity
-23.8%
This company
18.4%
Market median
-229% vs market
2020
2021
Net profit margin
-1000000.0%
This company
8.1%
Market median
-12345779% vs market
2020
2021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2020
2021
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
2020
2021
Annual reports & filings
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
LJ
Lars Johan Gunnar Moberg
Liquidator
Liquidator
2022
—
—
PJ
Per Johan Anders Källstrand
Chief Executive Officer
Chief Executive Officer
2020
—
—
Board of directors
Non-executive oversight
Name
Role
Member since
Age
Other directorships
PA
Per Andreas Nyberg
Chairman
2020
—
—
MT
Mohamad Takwa
Board of Directors
2020
—
—
KP
Kushagr Punyani
Board of Directors
2020
—
—
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Alvo Pharma AB also hold positions in
0
other companies.
Person
Role here
Other companies
Lars Johan Gunnar Moberg
Liquidator
0 companies
Per Johan Anders Källstrand
Chief Executive Officer
0 companies
Per Andreas Nyberg
Chairman
0 companies
Mohamad Takwa
Board of Directors
0 companies
Kushagr Punyani
Board of Directors
0 companies